Valion Bio’s RSU Grants Signal Strategic Shift Toward Entolimod Success
Valion Bio’s latest insider RSU grant signals a strategic pivot toward its Entolimod candidate, showcasing long‑term executive alignment and liquidity preservation while investors eye upcoming clinical milestones and partnership prospects.
5 minutes to read